Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Bortezomib-based Graft-Versus-Host-Disease Prophylaxis After Myeloablative Allogeneic Stem Cell Transplantation for Patients Lacking HLA-matched Related Donors: A Phase 2 Study
Status: Enrolling
Updated:  8/9/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Bortezomib-based Graft-Versus-Host-Disease Prophylaxis After Myeloablative Allogeneic Stem Cell Transplantation for Patients Lacking HLA-matched Related Donors: A Phase 2 Study
Status: Enrolling
Updated: 8/9/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Los Angeles, CA
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Miami, FL
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Athens, GA
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Athens, GA
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Idaho Falls, ID
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Iowa City, IA
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Topeka, KA
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Topeka, KA
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Lansing, MI
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Minneapolis, MN
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Fargo, ND
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Fargo, ND
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Philadelphia, PA
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Rapid City, SD
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Rapid City, SD
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Chattanooga, TN
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Fort Worth, TX
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Norfolk, VA
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Burlington, WI
A Study for Patients With Pancreatic Cancer
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Burlington, WI
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Fayetteville, AK
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Fayetteville, AK
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Aurora, CO
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Washington,
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Miami, FL
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Athens, GA
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Athens, GA
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Iowa City, IA
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Topeka, KA
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Topeka, KA
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Alexandria, LA
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Alexandria, LA
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Scarborough, ME
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Scarborough, ME
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Bethesda, MD
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Boston, MA
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Lansing, MI
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Minneapolis, MN
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Kansas City, MO
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Missoula, MT
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Missoula, MT
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Omaha, NE
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Las Vegas, NV
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Bridgewater, NJ
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Bridgewater, NJ
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Brooklyn, NY
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Muskogee, OK
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Muskogee, OK
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Charleston, SC
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
American Fork, UT
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
American Fork, UT
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Norfolk, VA
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Seattle, WA
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Burlington, WI
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Burlington, WI
Click here to add this to my saved trials
A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
Phase 1 Dose Escalation Study of LY2334737 Using 2 Dosing Regimens in Patients With Advanced and/or Metastatic Solid Tumors
Status: Enrolling
Updated:  8/10/2012
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
Phase 1 Dose Escalation Study of LY2334737 Using 2 Dosing Regimens in Patients With Advanced and/or Metastatic Solid Tumors
Status: Enrolling
Updated: 8/10/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Status: Enrolling
Updated:  8/14/2012
Saint Agnes Healthcare
mi
from
Baltimore, MD
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Status: Enrolling
Updated: 8/14/2012
Saint Agnes Healthcare
mi
from
Baltimore, MD
Click here to add this to my saved trials